TY - JOUR
T1 - Autoantibodies targeting G protein-coupled receptors
T2 - An evolving history in autoimmunity. Report of the 4th international symposium
AU - Cabral-Marques, Otávio
AU - Moll, Guido
AU - Catar, Rusan
AU - Preuß, Beate
AU - Bankamp, Lukas
AU - Pecher, Ann Christin
AU - Henes, Joerg
AU - Klein, Reinhild
AU - Kamalanathan, A. S.
AU - Akbarzadeh, Reza
AU - van Oostveen, Wieke
AU - Hohberger, Bettina
AU - Endres, Matthias
AU - Koolmoes, Bryan
AU - Levarht, Nivine
AU - Postma, Rudmer
AU - van Duinen, Vincent
AU - van Zonneveld, Anton Jan
AU - de Vries-Bouwstra, Jeska
AU - Fehres, Cynthia
AU - Tran, Florian
AU - do Vale, Fernando Yuri Nery
AU - da Silva Souza, Kamilla Batista
AU - Filgueiras, Igor Salerno
AU - Schimke, Lena F.
AU - Baiocchi, Gabriela Crispim
AU - de Miranda, Gustavo Cabral
AU - da Fonseca, Dennyson Leandro Mathias
AU - Freire, Paula Paccielli
AU - Hackel, Alexander M.
AU - Grasshoff, Hanna
AU - Kerstein-Stähle, Anja
AU - Müller, Antje
AU - Dechend, Ralf
AU - Yu, Xinhua
AU - Petersen, Frank
AU - Sotzny, Franziska
AU - Sakmar, Thomas P.
AU - Ochs, Hans D.
AU - Schulze-Forster, Kai
AU - Heidecke, Harald
AU - Scheibenbogen, Carmen
AU - Shoenfeld, Yehuda
AU - Riemekasten, Gabriela
N1 - Publisher Copyright:
© 2023
PY - 2023/5
Y1 - 2023/5
N2 - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.
AB - G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=85150078492&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/f59ca7b3-739e-3568-a0f7-cb4f21955627/
U2 - 10.1016/j.autrev.2023.103310
DO - 10.1016/j.autrev.2023.103310
M3 - Scientific review articles
C2 - 36906052
AN - SCOPUS:85150078492
SN - 1568-9972
VL - 22
SP - 103310
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 5
M1 - 103310
ER -